Equity Profile

ZLAB

Zai Lab Limited

Health CareBiotechnology$2.2B

Nov29Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close9:00 AM EST

Company Snapshot

Zai Lab Limited is a biotechnology company focused on developing innovative medicines to address unmet medical needs. Operating in the health care sector, Zai Lab is involved in the research and commercialization of therapies for various diseases, making it a key player in the biotechnology industry.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ZLAB Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+0.83%

Avg Stock Reaction

-3.30%

Last Quarter Recap

In the last quarter, Zai Lab reported an EPS of -$0.46, which was better than the expected -$0.58, resulting in a positive surprise. However, the stock price fell by nearly 6% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Zai Lab's upcoming earnings are uncertain, given the lack of analyst estimates and management guidance. Investors will be closely monitoring the company's performance against its historical trends.

Bull Case

If Zai Lab can report a smaller-than-expected loss or show signs of revenue growth, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss or fails to demonstrate progress in its product pipeline, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter?

Given the recent EPS surprises, the market will closely watch this figure to gauge the company's financial health.

What updates can be provided on product development and revenue generation?

Insights into product pipeline progress and revenue potential are critical for understanding the company's future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Zai Lab's potential for a smaller-than-expected loss due to recent positive developments in its product pipeline.

Supporting Evidence

The company's historical EPS surprises suggest potential for better-than-expected results.

Options pricing indicates high volatility, which could reflect investor optimism not captured in analyst estimates.

Key Risk

If the EPS comes in better than -$0.40, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether Zai Lab can stabilize its financials and regain investor confidence.

Bull Confirmed If

A reported EPS loss of less than -$0.40 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±32.08%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±32.1% while ZLAB has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

60.2%

Calls (400)P/C Ratio: 52.33Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zai Lab beats expectations, history suggests a potential stock increase of around 5.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 1.1%, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key drug candidates in the pipeline.
2Management's outlook on revenue generation for the upcoming quarters.
3Details on cost management and operational efficiency improvements.
4Insights into market conditions and competitive landscape affecting sales.
5Any commentary on partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

The Buckle, Inc.

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ZLAB Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+0.83%

Avg Stock Reaction

-3.30%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Zai Lab can report a smaller-than-expected loss or show signs of revenue growth, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss or fails to demonstrate progress in its product pipeline, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter?

Given the recent EPS surprises, the market will closely watch this figure to gauge the company's financial health.

What updates can be provided on product development and revenue generation?

Insights into product pipeline progress and revenue potential are critical for understanding the company's future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Zai Lab's potential for a smaller-than-expected loss due to recent positive developments in its product pipeline.

Supporting Evidence

The company's historical EPS surprises suggest potential for better-than-expected results.

Options pricing indicates high volatility, which could reflect investor optimism not captured in analyst estimates.

Key Risk

If the EPS comes in better than -$0.40, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be pivotal in determining whether Zai Lab can stabilize its financials and regain investor confidence.

Bull Confirmed If

A reported EPS loss of less than -$0.40 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±32.08%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±32.1% while ZLAB has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

60.2%

Calls (400)P/C Ratio: 52.33Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zai Lab beats expectations, history suggests a potential stock increase of around 5.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 1.1%, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key drug candidates in the pipeline.
2Management's outlook on revenue generation for the upcoming quarters.
3Details on cost management and operational efficiency improvements.
4Insights into market conditions and competitive landscape affecting sales.
5Any commentary on partnerships or collaborations that could enhance growth.